Open navigation

Media Center

Press Releases

Using Mono-allelic Mass Spectrometry Data to Improve Epitope Prediction Algorithms Published in Immunity

Neon Therapeutics to Present at 35th Annual J.P. Morgan Healthcare Conference

Neon Therapeutics Announces First Patient Enrolled in Inaugural Clinical Trial for Personalized Cancer Vaccine NEO-PV-01

Neon Therapeutics Appoints Dr. Richard Gaynor to President of Research and Development

Neon Therapeutics Appoints Oncology Veteran Hugh O’Dowd to Chief Executive Officer

FierceBiotech names Neon Therapeutics as one of its “Fierce 15” Biotech Companies of 2016

Neon Therapeutics Announces FDA Acceptance of Investigational New Drug  Application for Cancer Vaccine NEO­-PV­-01

Neon Therapeutics Enters Collaborative Research Agreement with the Netherlands Cancer Institute

Neon Therapeutics Enters License Agreement with Sanquin for Peptide-MHC Assay Technology


Founders' & Advisors' Publications

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

N.A. Rizvi, P. Kvistborg, T.N. Schumacher, et al. SCIENCE. 2015

Checkpoint blockade cancer immunotherapy targets tumor-specific mutant antigens

M.M. Gubin, T.N. Schumacher, R.D. Schreiber, et al. NATURE. 2014

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

R.S. Herbst, H.E. Kohrt, et al. NATURE. 2014

Neoantigens in cancer immunotherapy

T.N. Schumacher, R.D. Schreiber. SCIENCE. 2015

Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines

N. HacohenE.F. Fritsch, T.A. Carter, et alCANCER IMMUNOLOGY RESEARCH. 2013


Neon Team Publications

Molecular and genetic properties of tumors associated with local immune cytolytic activity

M.S. Rooney, C.J. Wu, N. Hacohen, et al. CELL. 2015

Biomarkers in Cancer Immunotherapy

T.N. Schumacher, M.M. van Buuren, et al. CANCER CELL. 2015

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

Linneman, M.M. van Buuren, T.N. Schumacher, et al. NATURE MEDICINE. 2015

Personal neoantigen cancer vaccines: The momentum builds

E.F. Fritsch, N. Hacohen, C.J. WuONCOIMMUNOLOGY. 2014

HLA-binding properties of tumor neoepitopes in humans

E.F. Fritsch, M. Rajasagi, P.A. Ott, et alCANCER IMMUNOLOGY RESEARCH. 2014